Study of OR502 alone and with other cancer treatments
Treatments studied
Part of Cancer, Lungs & breathing, Skin clinical trials.
This trial tests an experimental drug called OR502, which targets a protein on immune cells, to see if it can help fight advanced solid tumors. It is given alone or with other anti-cancer drugs, and the study aims to find the best dose and see how well it works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a type of advanced cancer (carcinoma, sarcoma, or melanoma) that has spread or cannot be removed with surgery.
- You must have already tried at least one standard cancer treatment that stopped working or caused bad side effects.
- You must be willing to provide a stored tumor tissue sample or have one available.
- You must have measurable tumors that can be tracked with imaging scans.
- You must be in generally good health, with no serious infections, autoimmune diseases, or uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
This trial tests an injected study drug (ONM-501) alone or with another drug (cemiplimab) for people with advanced solid tumors or lymphomas that haven't responded to other treatments. It aims to find a safe dose and see if the combination helps shrink or control the cancer.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
This trial tests an experimental drug called OBI-902 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if OBI-902 can help shrink or control the cancer.
This Phase 1 trial tests KM602, a new study treatment, in people with advanced solid tumors like melanoma or non-small cell lung cancer that have progressed after standard treatments. If you qualify, the goal is to see how the drug works and how safe it is in early research.
This trial tests a combination of two new drugs, BND-22 and cemiplimab, for people with certain advanced solid tumors like lung, colorectal, or ovarian cancer. It aims to see if this treatment helps control the cancer and looks at specific markers in your blood and tissue.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.